TNTs‐mediated transfer of tumor‐derived AA reprograms TAMs via PI3K‐AKT activation, promoting immune suppression and tumor progression, highlighting TNTs and PI3K‐AKT as potential therapeutic targets in iCCA. The gene discussed is AKT1; the disease is infantile convulsions and choreoathetosis.